Treprostinil (CAS 81846-19-7)
See product citations (1)
QUICK LINKS
Primary pulmonary hypertension (PPH) is characterized by increasing pulmonary arterial and vascular resistance, and the cause is unknown. This compound is a stable analog of prostacyclin that is used clinically for the treatment of PPH under the trade name Remodulin®. The structural modifications in treprostinil compared to prostacyclin increase the plasma half-life from 2 minutes to 34 and 85 minutes for intravenous and subcutaneous infusion of the drug, respectively. In addition to treprostinil′s direct vasodilatory effects, it also inhibits inflammatory cytokine (TNFα, IL-1β, IL-6, GM-CF) production by human alveolar macrophages in the sub-micromolar range by preventing NF-κB translocation to the nucleus.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Treprostinil, 1 mg | sc-205533 | 1 mg | $158.00 | |||
Treprostinil, 5 mg | sc-205533A | 5 mg | $712.00 | |||
Treprostinil, 10 mg | sc-205533B | 10 mg | $1200.00 |